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Background. Broad-range 16S ribosomal RNA (rRNA) gene polymerase chain reaction (PCR) is used for
detection and identification of bacterial pathogens in clinical specimens from patients with a high suspicion for
infection. However, prospective studies addressing the impact and clinical value of broad-range bacterial 16S rRNA
gene amplification for diagnosis of acute infectious diseases in nonselected patient populations are lacking.
Methods. We first assessed the diagnostic performance of 16S rRNA gene PCR compared with routine bacterial
culture. Second, we addressed prospectively the impact and clinical value of broad-range PCR for the diagnosis of
acute infections using samples that tested negative by routine bacterial culture; the corresponding patients’ data
were evaluated by detailed medical record reviews.
Results. Results from 394 specimens showed a high concordance of.90% for 16S rRNA gene PCR and routine
bacterial culture, indicating that the diagnostic performance of PCR for acute bacterial infections is comparable to
that of bacterial culture, which is currently considered the gold standard. In thisprospective study, 231 specimens
with a negative result on routine bacterial culture were analyzed with PCR, and patients’ clinical data were reviewed.
We found that broad-range 16S rRNA gene PCR showed a sensitivity, specificity, positive predictive value, and
negative predictive value of 42.9%, 100%, 100%, and 80.2% for culture-negative bacterial infections.
Conclusions. This study defines the role of 16S rRNA gene PCR for diagnosis of culture-negative bacterial
infections. Our data show that 16S rRNA gene PCR is particularly useful for identification of bacterial pathogens in
patients pretreated with antibiotics.
Bacterial infections remain a leading cause of death [1]
and represent a massive financial burden to the health
care system [2]. The traditional microbiological workup
of clinical specimens is based on Gram staining, cultures
on variousmedia, and phenotypic identification schemes.
Over the past 2 decades, molecular genetic techni-
ques have been implemented for accurate pathogen
identification in diagnostic microbiology [2–10]. Broad-
range 16S ribosomal RNA (rRNA) gene polymerase
chain reaction (PCR) is used to detect and identify
bacterial pathogens in clinical specimens [11–14] (Sup-
plementary Table 1; online only), mostly in cases where
bacterial infection is suspected but cultures remain
negative [15–17]. Broad-range 16S rRNA gene PCR is
particularly suitable for bacteria that are difficult to
culture such as Mycobacterium genavense [18], Tro-
pheryma whipplei [19], Ehrlichia chaffeensis [20], and
Coxiella burnetii [21].
Despite the wide implementation of 16S rRNA gene
PCR [22–27], there are few evidence-based studies ad-
dressing systematically its diagnostic impact in non-
selected (random) patient populations, that is, in patients
suspected to have infectious disease but not limited to
particular disease entities. In addition, little information
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is available on how to effectively implement 16S rRNA gene PCR
in a diagnostic workflow. Here, we performed both a prospective
laboratory study to compare the diagnostic performance of PCR
with bacterial culture and a prospective clinical study to assess the
impact of broad-range PCR in the diagnosis of acute infection. In
particular, we studied an algorithm that is based on a broad-range
16S rRNA gene PCR for culture-negative specimens from patients
with suspected infectious disease.
METHODS
This study was approved by the ethical committee of the canton of
Zurich, Switzerland, and was done according to good clinical
practice. Study design was composed of a laboratory study and
a clinical study. In the laboratory study, specimens from primary
sterile body sites were subjected (in parallel) to conventional
microbiological culture (performed at the Institute for Clinical
Microbiology and Immunology in St Gallen, Switzerland) and
broad-range 16S rRNA gene PCR (performed at the Institute of
Medical Microbiology in Zurich), to compare the diagnostic
performance of PCR versus culture. In the clinical study, an al-
gorithm was used integrating the broad-range PCR into the di-
agnostic sample workup. In this algorithm, samples from primary
sterile body sites submitted to the microbiological laboratory were
subjected to broad-range PCR if cultures (including enriched
cultures) remained negative after 72 hours of incubation (all
analyses were performed at the Institute of Medical Microbiology
in Zurich). The clinical study is based on a prospective design as
related to the microbiological workup of culture-negative speci-
mens by 16S rRNA gene PCR; the patients’ medical histories were
reviewed retrospectively.
Clinical Specimens
Patient samples were obtained from 2 tertiary care hospitals, the
Kantonsspital St Gallen (KSSG) and the University Hospital of
Zurich (USZ). KSSG is an 860-bed hospital in the eastern part of
Switzerland; the samples fromKSSGwere used for the laboratory
study. USZ is an 850-bed academic center; the samples from
USZ were used for the clinical study.
Medical Record Review
Clinical data of the patients enrolled in the clinical study were
obtained by medical record review and analyzed for the like-
lihood of an infection. A panel of 2 senior infectious disease
consultants (S. K. R. and R. F. S.) and 3 senior microbiologists
(G. V. B., P. M. K., E. C. B.) discussed each case in depth and
categorized it as definite, likely, unlikely, or no infection.
Criteria included clinical signs and symptoms, chemistry pa-
rameters (eg, leukocyte count, C-reactive protein, procalcito-
nin), microbiological findings (eg, serology, previous culture
results), radiological findings, previous antibiotic treatment,
and clinical diagnosis [28]. In the final analysis, we added
patients with ‘‘likely infection’’ to the ‘‘definite infection’’
category, and we excluded patients with ‘‘unlikely infection’’
from the study to minimize false interpretations. In general,
scoring of patients on the basis of medical record review was
done blinded to the 16S rRNA gene PCR results. When data
were not unequivocally clear, all data available, including the
results of microbiological analysis, were considered. We de-
fined all patients who received antibiotics, including peri-
operative antibiotic prophylaxis, within 21 days prior to
sampling as treated. This definition did not take into account
whether the eventual microorganism identified was susceptible
to the antibiotic prescribed.
Microbiological Analyses
Microscopy
Gram stains of clinical specimens were prepared according to
standard procedures. The mean bacterial count was determined
from ten 1000-fold visual fields (,5; 5–25;.25 bacteria per visual
field) and the mean count for leukocytes from ten 100-fold
magnified fields (1–9; 10–25; .25 leukocytes per field).
Cultures
Cultures were performed as described elsewhere [7, 8]. In brief,
solid and tissue samples were placed in sterile 0.9% sodium
chloride solution following retrieval, minced upon receipt in the
laboratory using an Ultra-Turrax tissue homogenizer (IKA),
inoculated for culture, and incubated under aerobic and an-
aerobic conditions. An anaerobic glove box (DW Scientific) with
prereduced anaerobic media was used for anaerobic culturing
conditions. Aerobic media included Columbia blood agar,
MacConkey agar, colistin nalidixin acid (CNA) blood agar, and
Crowe agar [29]. Anaerobic media included Brucella agar,
kanamycin-vancomycin agar, and phenylethyl alcohol agar.
Thioglycolate broth was used for enrichment cultures. Agar
plates were examined for growth after 24, 48, and 72 hours.
Optical turbidity of the liquid enrichment medium was in-
spected after 1, 2, 3, and 10 days of incubation. Cultures were
considered negative if no bacterial growth was visible after 10
days of incubation. For the laboratory study, this period was
extended to 14 days. Liquid samples were inoculated into aer-
obic and anaerobic BacT/Alert Blood Culture flasks (Bio-
Me´rieux) for enrichment cultures and incubated in a BacT/Alert
system for 6 days. Flasks with a positive growth signal were
subcultured using the set of agar-based media described above.
DNA Extraction and Polymerase Chain Reaction
DNA extraction and 16S rRNA gene PCR was done as described
previously [7]. Escherichia coli chromosomal DNA was used as
a positive control. As negative control buffers, PCR reagents and
elution column solutions were routinely tested for bacterial
DNA contamination. If bacterial identification in a clinical
sample was identical to the bacterial DNA contamination in 1 of
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the negative controls (,5% of the samples), this sample was
considered PCR negative. 16S rRNA gene homology analyses
were done using the SmartGene IDNS database and software
[30] (SmartGene).
Statistical Methods
The statistical methods used are described in the text or in the
figure legend related to the dataset analyzed. Statistical calcu-
lations were done using GraphPad Prism software, version 5.02
(GraphPad Software).
RESULTS
Sensitivity and Specificity of Broad-Range 16S rRNA Gene
Polymerase Chain Reaction Compared With Conventional
Culture (Laboratory Study)
To determine the minimal number of bacterial chromosomal
copies, serial dilutions of E. coli (Gram-negative) and Staphylo-
coccus aureus (Gram-positive) DNA were subjected to broad-
range 16S rRNA gene PCR. The detection limit of the procedure
using polyacrylamide gel electrophoresis and silver staining to
resolve 16S rRNA gene PCR amplicons was consistently 40 gene
copies per reaction.
We prospectively assessed 16S rRNA gene PCR compared with
conventional culture. The study period was from July 2008 to
December 2008 and included 394 samples from primary sterile
body sites of a nonselected patient population. In this laboratory
study, clinical data were not taken into account. There was a high
concordance of both culture and PCR in 357 of 394 (90.6%)
analyses (Tables 1 and 2). Discordant results were observed in
37 cases with 18 (4.6%) culture-negative, PCR-positive results
and 19 (4.8%) culture-positive, PCR-negative results. Species
assignments in the 18 culture-negative, PCR-positive samples
(Table 2) included Staphylococcus spp (n 5 5), Streptococcus spp
(n 5 3), Ralstonia spp (n 5 2), Acinetobacter spp (n 5 2),
Burkholderia sp (n 5 1), E. coli (n 5 1), Citrobacter freundii
(n 5 1), Haemophilus influenzae (n 5 1), Porphyromonas asac-
charolyticus (n 5 1), and Peptinophilus sp (n 5 1). Ralstonia spp
(n5 2), Acinetobacter spp (n5 2), and Burkholderia spp (n5 1)
were considered to represent laboratory or sample retrieval
contaminants (5 of 104 PCR-positive results). The isolates
identified in the 19 culture-positive, PCR-negative specimens
(Table 2) included Propionibacterium acnes (n 5 11), co-
agulase-negative staphylococci (n 5 5), S. aureus (n 5 2), and
Staphylococcus lugdunensis (n 5 1). Fifteen of 19 culture-pos-
itive, PCR-negative samples had only very low numbers of
bacteria present as indicated by the observation that these
samples showed bacterial growth only after several days of in-
cubation in enriched liquid culture medium (Table 2).
Broad-Range 16S rRNA Gene Polymerase Chain Reaction for
Diagnosis of Infections in Culture-Negative Samples (Clinical
Study)
In the clinical study, we prospectively enrolled all patient
specimens received from July 2008 to December 2008 (n5 231;
Figure 1) for which bacterial cultures had remained negative for
growth after 3 days of incubation. The likelihood of infection was
retrospectively judged on the basis of clinical and laboratory
data. Data were obtained by detailed patient medical record
review. Incorporating the different parameters resulted in a final
categorization of definite infection or no infection.
Thirty-two samples were excluded because of unavailable or
insufficient patient documentation or because cultures became
positive after prolonged incubation (Figure 1). Five of 29
culture-negative, PCR-positive and 8 of 170 culture-negative,
PCR-negative samples were excluded because no firm clinical
assignment was possible (Figure 1). In total, 186 specimens
were included in the analysis: aspirates and biopsies (n 5 97),
cerebrospinal fluids (n 5 40), tissues (n 5 21), heart valves
(n5 11), wound swabs (n5 11), abscess materials (n5 4), and
ascites (n 5 2).
Twenty-four of 186 samples were PCR positive and included
the following species: Streptococcus spp (n5 6), S. aureus (n5 4),
Ureaplasma urealyticum (n 5 3), Staphylococcus epidermidis
(n5 3),C. burnetii (n5 2), Porphyromonas endodontalis (n5 3),
Fusobacterium nucleatum (n 5 1), species of the family En-
terobacteriaceae (n 5 1), Enterococcus faecalis (n 5 1), and
Parvimonas micra (n5 1) (Table 3). All of the 24 PCR-positive
samples were from patients categorized as having definite in-
fection. Of 186 samples, 162 were negative by broad-range
PCR, including 32 patients with definite infection and 130
patients considered to have no infection based on detailed
medical record reviews (Figure 1). The sensitivity of broad-
range 16S rRNA gene PCR in correctly diagnosing bacterial
infection for culture-negative samples was 42.9 %, the speci-
ficity was 100%, the positive predictive value (PPV) was 100%,
and the negative predictive value (NPV) was 80.2% (Supple-
mentary Table 2.1; online only).
Seventy-nine of 186 specimens were obtained from patients
who had previously been treated with antibiotics or who were
undergoing antibiotic treatment when the clinical specimen was




PCR 1 86 (21.8%) 18 (4.6%)
– 19 (4.8%) 271 (68.8%)
A total of 394 clinical specimens were included in the study. For bacterial
identification see Table 2.
Abbreviations: PCR, polymerase chain reaction; –, negative; 1, positive.
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obtained. It is noteworthy that all 24 specimens with culture-
negative, PCR-positive results (Table 3) were obtained from this
patient group. Thirty-one of 55 specimens of the antibiotic-
treated patients with culture-negative, PCR-negative results were
categorized as definite infection. The sensitivity of broad-range
16S rRNA gene PCR in correctly diagnosing bacterial infection
for culture-negative samples from patients undergoing or having
previously undergone antibiotic therapy was 43.6 %, the speci-
ficity was 100%, the PPV was 100%, and the NPV was 43.6 %
(Supplementary Table 2.2; online only).
There was a single patient with a clinically well-defined in-
fection who was antibiotic naive and whose sample culture was
16S rRNA gene PCR negative (Supplementary Table 2.3; online
only). This case was eventually identified as Mycobacterium che-
lonae infection by Mycobacterium genus–specific PCR. All other
specimens from antibiotic-naive patients (106 samples) were
from cases we categorized as no infection.
Five of 24 culture-negative, PCR-positive specimens (Table 3)
were obtained from patients recovered from infectious endo-
carditis (IE) following antibiotic therapy (samples 1, 2, 7, 12, and
21; Table 3). There was complete agreement between the culture
results from the specimens obtained before antibiotic treatment
and PCR results obtained when the heart valve was replaced
during antibiotic treatment. Two of 24 specimens with culture-
negative, PCR-positive results were from 2 patients who had
perioperative prophylaxis at the time the specimen was retrieved
(samples 3 and 18; Table 3). The remaining 17 culture-negative,
PCR-positive samples were retrieved from patients who had
been treated with antibiotics for various periods of time. To
assess a possible impact of the duration of antibiotic therapy on
pathogen detection by PCR, a comparison was made for PCR-
positive (n 5 24) and PCR-negative (n 5 31) specimens from







Cupriavidus metallidurans 1 Acinetobacter johnsonii 1 Propionibacterium acnes 11c
Enterobacter cloacae 1 Acinetobacter sp 1 Staphylococcus lugdunensis 1
Enterobacter sp 10 Burkholderia sp 1 Staphylococcus aureus 2
Enterobacteriaceae 3 Citrobacter freundii 1 Staphylococcus capitis 1
Enterococcus faecalis 1 Enterobacteriaceae 1 Staphylococcus epidermidis 3
Enterococcus faecium 1 Haemophilus influenzae 1 Staphylococcus sp 1
Morganella morganii 2 Peptoniphilus sp 2
Paenibacillaceae 1 Porphyromonas asaccharolyticus 1
Proteus sp 1 Ralstonia insidiosa 1
Proteus vulgaris 3 Ralstonia pickettii 1
S. aureus 32 S. aureus 2
S. epidermidis 19 S. epidermidis 1
Streptococcus agalactiae 5 Staphylococcus sp 2
Streptococcus dysgalactiae 1 S. agalactiae 1
Streptococcus sp 5 Streptococcus infantis 1
Streptococcus sp 1
Total 86 Total 18 Total 19
Abbreviation: PCR, polymerase chain reaction.
a Ralstonia spp, Acinetobacter spp, and Burkholderia spp were considered laboratory or sample retrieval contaminations (5 of 104 PCR-positive results).
b Fifteen of 19 specimens were positive by culture only following prolonged incubation (.48 hours) with monitoring up to 14 days in enriched broth medium; 1 of 19
specimens was positive by culture with a single colony-forming unit; 3 of 19 specimens were positive by culture within 48 hours of incubation (for these 3 samples
the corresponding isolate was identified by PCR in a second specimen of the respective patient).
c Four cultures became positive after .10 days of incubation.
Figure 1. Enrollment of specimens in the clinical study. aCulture
negative for 3 days. bUSZ, University Hospital Zu¨rich. PCR, polymerase
chain reaction.
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patients with acute infections treated with antibiotics for various
periods of time. For simplicity, we categorized clinical specimens
into groups obtained within the first 10 (n 5 28), 20 (n 5 11),
30 (n5 5), 40 (n5 5), 50 (n5 4), and 60 (n5 2) days after start
of antibiotic treatment. Similar numbers of positive and negative
PCR results were observed in all specimen groups, indicating
that PCR positivity is independent of the duration of antibiotic
treatment (at least up to 60 days).
DISCUSSION
Clinicians are frequently challenged with the suspicion of acute
infectious diseases even when a conventional microbiological
workup remains negative. Broad-range PCR detects many clin-
ical relevant bacteria as documented by the bacterial assignments
obtained during 2005–2008 (Supplementary Table 1; online
only). The primary goal of this study was to assess the value of
16S rRNA gene PCR for the diagnosis of acute bacterial in-
fections in a nonselected patient population, in particular, to
provide evidence-based data to the clinician for a targeted use of
broad-range 16S rRNA gene PCR.
In the laboratory part of the study, we analyzed the di-
agnostic sensitivity and specificity of broad-range PCR in
394 specimens compared with routine bacterial culture. We
found that the concordance between 16S rRNA gene PCR and
culture is .90%. The sensitivity of broad-range PCR in our
dataset was 81.9% and the specificity 93.8%. A recent study
reported a sensitivity of 93% and a specificity of 72% for 16S
rRNA gene PCR compared with conventional culture [31].
The differences in sensitivity and specificity between our




















1 Aortic valve nd 1 Streptococcus mutans 0/32
2 Mitral valve nd 11 Enterococcus faecalis 0/54
3 Deep wound (swab) 11 (Gram-positive cocci) 111 Parvimonas micra 0/1
4 Cerebrospinal fluid 11 (Gram-positive cocci) 111 Staphylococcus aureus 0/2
5 Sternal wound (swab) nd 111 Staphylococcus epidermidis 0/3
6 Cerebrospinal fluid 111 nd S. epidermidis 0/16
7 Mitral valve nd 1 S. aureus 0/48
8 Abscess (brain)d nd nd Fusobacterium nucleatum
Porphyromonas endodontalis
0/7
9 Abscess (brain)d nd nd P. endodontalis 0/7
10 Aspirate (shoulder) nd 111 Streptococcus dysgalactiae 20/39
11 Abscess (brain) 1 (Gram-positive cocci) 111 Streptococcus intermedius 0/12
12 Aortic valve 111 (Gram-positive cocci) 1 Streptococcus sp (Streptococcus
mitis group)
0/2
13 Pleural effusion nd 111 P. endodontalis 0/28
14 Sternal wound (swab) nd 1 S. epidermidis 0/49
15 Aspirate (knee) nd 111 Enterobacteriacea 0/5
16 Tissue nd 111 S. aureus 0/3
17 Tissue nd 111 S. aureus 0/3
18 Abscess (psoas muscle) nd 11 Coxiella burnetii 0/1
19 Tissue (aneurysma) nd 1 C. burnetii 0/7
20 Aortic valve nd 111 Streptococcus sp. (S. mitis group) 21/42
21 Mitral valve nd 1 S. mitis 0/25
22 Sternal wound (swab) nd 1 Ureaplasma urealyticum 0/4
23 Sternal wound (swab) nd 1 U. urealyticum 0/4
24 Sternal wound (swab) nd 11 U. urealyticum 0/4
Abbreviations: nd, not detected; PCR, polymerase chain reaction; pos, positive; rRNA, ribosomal RNA.
a Bacterial cell count in ten 1000-fold visual fields: 1, ,5; 11, 5–25; 111, .25.
b Leukocyte count in ten 100-fold magnified fields: 1, 1–9; 11, 10–25; 111, .25.
c 0/32 indicates that the specimen was obtained while the patient was under antibiotic therapy and had received antibiotic therapy for the past 32 days; 20/39
indicates that the specimen was retrieved 20 days after an antibiotic therapy of 39 days; 0/1 indicates that the specimen was retrieved at the start of antibiotic
therapy.
d This case was recently published in detail [17].
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study and the earlier study most likely reflect the parallel
workup of samples retrieved from primary sterile compart-
ments by both culture and broad-range PCR in our study, that
is, the nonselective use of 16S rRNA gene PCR. The high
concordance between culture and PCR indicates a similar
analytical sensitivity.
In the clinical part of this study, we assessed the diagnostic
power of broad-range 16S rRNA PCR in the diagnosis of acute
bacterial infections for which conventional cultures were negative
and the likelihood of infection was assessed. Notably, the majority
of samples submitted for microbiological analysis (130 of 186)
were obtained from patients without firm evidence of infection as
judged by retrospective medical record review. This high number
of patients without infection reflects the difficulty of accurately
diagnosing infection at the bedside, emphasizing the need of an
interdisciplinary approach toward accurate diagnosis in which the
clinical presentation, the laboratory findings, and the imaging all
contribute to reach the final diagnosis.
The importance of 16S rRNA gene PCR is demonstrated in the
clinical part of the study, where a pathogen was identified in
42.9% of the culture-negative specimens of patients with clear
evidence of an infection as indicated by detailed medical record
review (Table 3). The relatively high number of specimens with
culture-negative, PCR-negative results reflects the prevalence of
patients with sterile inflammatory processes (eg, elevated leuko-
cyte counts in joint aspirates due to rheumatoid arthritis). The
PPV of the 16S rRNA gene PCR was 100%, indicating that
a positive result accurately identifies an infection. We are aware
that a specificity and a PPV of 100% of broad-range PCR in the
clinical study should be viewed with caution, as 5 of 104 positive
PCR results in the laboratory study were thought to be due to
environmental contaminants. Due to restrictions inherent in
a clinical study design (ie, the necessity to exclude patients for
whom no firm diagnosis could be established), we had to elim-
inate 5 of 29 PCR-positive and 8 of 170 PCR-negative samples
from the clinical study (Figure 1). If we include these samples in
the no-infection category, the specificity, PPV, and NPV of
broad-range PCR are 96.5%, 82.8%, and 81.2%, respectively.
A subanalysis revealed that the NPV was 99.1% for the patients
who had not received antibiotics prior to sampling.
In the clinical study, 16S rRNA gene PCR was positive exclu-
sively in patients who had previously undergone antibiotic
treatment. This finding, together with the similar analytical sen-
sitivity of culture and PCR as found in the laboratory study,
suggests that carrying out 16S rRNA gene PCR and bacterial
culture in parallel in antibiotic-naive patients will not aid sub-
stantially in diagnosing infections. The vast majority of antibiotic
prescriptions (.90%) are in the outpatients [32], and a sub-
stantial number of patients suffering from bacterial infections will
have received antibiotics prior to hospital admission. This patient
group frequently poses a diagnostic dilemma, as the cultures of
the causative infectious pathogen often remain negative. For this
patient group, broad-range 16S rRNA PCR is particularly valu-
able and may add key diagnostic findings to improve patient
management.
We also analyzed a possible influence of the length of antibiotic
prescription on the detection of pathogens by 16S rRNA gene
PCR, as we assumed that PCR positivity will decline with the
duration of antibiotic therapy preceding clinical specimen re-
trieval. However, the ratio of PCR-positive and PCR-negative
samples was independent of the length of prior antibiotic therapy
(as analyzed for a maximum period of 60 days).
The majority of pathogens identified in the culture-negative,
PCR-positive group of the clinical study were common patho-
gens, which usually grow without any particular requirements.
There were 2 exceptions in this part of the study (Table 3):
C. burnetii (recovered twice), which exclusively grows in cell
culture or needs to be inoculated into laboratory animals [21],
and U. urealyticum (recovered 3 times), which requires cultiva-
tion on selective medium for Mycoplasmataceae (retrospective
inoculation of selective medium demonstrated the presence of
U. urealyticum in all 3 samples). It goes without saying that
common pathogens were more frequently found in the clinical
study, as the number of infections with difficult-to-culture
pathogens is low compared with common pathogens (see also
Table 1; online only). From a clinical point of view, however, it is
as important to recognize infections with unusual pathogens in
a reliable manner as those due to common pathogens.
In summary, this study shows that there is a high concordance
between broad-range 16S rRNA gene PCR and culture in path-
ogen detection and that broad-range PCR is particularly valuable
for patients under antibiotic therapy. On the basis of our data, we
propose that broad-range PCR of samples from primary sterile
body sites should be done for patients with a high clinical sus-
picion of infection and negative culture results. The suspicion for
infections with difficult-to-culture pathogens justifies a broad-
range PCR on its own, in particular when a species-specific
molecular test is not available. Implementing an algorithm that
excludes culture-positive samples is both diagnostically and eco-
nomically feasible.
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